Health & Fitness
Health and Fitness
Health and Fitness
Thu, March 7, 2013Wed, March 6, 2013Tue, March 5, 2013Mon, March 4, 2013Sun, March 3, 2013Sat, March 2, 2013Fri, March 1, 2013Thu, February 28, 2013Wed, February 27, 2013Tue, February 26, 2013Mon, February 25, 2013Sun, February 24, 2013Sat, February 23, 2013Fri, February 22, 2013Thu, February 21, 2013Wed, February 20, 2013Tue, February 19, 2013Mon, February 18, 2013Sun, February 17, 2013Fri, February 15, 2013Thu, February 14, 2013Wed, February 13, 2013Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
Published in Health and Fitness on Tuesday, February 26th 2013 at 5:45 GMT by Market Wire
Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference... -- BRIDGEWATER, N.J., Feb. 26, 2013 /PRNewswire/ --
BRIDGEWATER, N.J., Feb. 26, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: [ SVNT ]) announced today that the Company's fourth quarter and year-end 2012 financial results will be released prior to the market open on Tuesday, March 19, 2013. Savient's executive management will host a conference call beginning at 9:00 a.m. Eastern Time on March 19, 2013, to discuss these results and to answer questions.
To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 99134844. The live and archived webcast can be accessed via the Investor Relations section of the Savient website at [ www.savient.com ]. A telephone replay will be available from 12:00 p.m. Eastern Time on March 19, 2013, through 11:59 p.m. Eastern Time on March 25, 2013, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 99134844.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. In the U.S., Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII and co-promotes Kineret® (anakinra) with Swedish Orphan Biovitrum AB (Sobi). For more information, please visit the Company's website at [ www.savient.com ].
SVNT-I
CONTACT: | |
Savient Pharmaceuticals, Inc. | Burns McClellan |
John P. Hamill | Caitlyn Murphy |
Senior Vice President and Chief Financial Officer | |
(212) 213-0006 | |
(732) 418-9300 |
SOURCE Savient Pharmaceuticals, Inc.
RELATED LINKS
[ http://www.savient.com ]
